NASDAQ:PROF Profound Medical (PROF) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free PROF Stock Alerts $8.53 +0.25 (+3.02%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$8.20▼$8.5350-Day Range$8.01▼$9.4652-Week Range$7.11▼$15.49Volume17,226 shsAverage Volume44,261 shsMarket Capitalization$208.39 millionP/E RatioN/ADividend YieldN/APrice Target$14.58 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Profound Medical alerts: Email Address Profound Medical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside71.0% Upside$14.58 Price TargetShort InterestHealthy1.31% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.66Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.17) to ($1.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.89 out of 5 starsMedical Sector619th out of 938 stocksSurgical & Medical Instruments Industry66th out of 97 stocks 3.5 Analyst's Opinion Consensus RatingProfound Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.58, Profound Medical has a forecasted upside of 71.0% from its current price of $8.53.Amount of Analyst CoverageProfound Medical has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.31% of the outstanding shares of Profound Medical have been sold short.Short Interest Ratio / Days to CoverProfound Medical has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Profound Medical has recently decreased by 2.26%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldProfound Medical does not currently pay a dividend.Dividend GrowthProfound Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PROF. Previous Next 2.0 News and Social Media Coverage News SentimentProfound Medical has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Profound Medical this week, compared to 2 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Profound Medical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.52% of the stock of Profound Medical is held by insiders.Percentage Held by Institutions47.86% of the stock of Profound Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Profound Medical are expected to grow in the coming year, from ($1.17) to ($1.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Profound Medical is -6.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Profound Medical is -6.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProfound Medical has a P/B Ratio of 6.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Profound Medical Stock (NASDAQ:PROF)Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.Read More PROF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PROF Stock News HeadlinesMarch 29, 2024 | msn.comFamily says Mayor Henry suffered medical emergency related to cancer diagnosisMarch 28, 2024 | markets.businessinsider.comPittsburgh PA Medical Malpractice Injury Attorneys Help Allegheny, Erie CountiesMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 28, 2024 | msn.comMeriem Zaourar Applies Her Profound AI Expertise to the Health IndustryMarch 28, 2024 | msn.com30 “Normal” Medical Issues People Overlooked Until Pointed OutMarch 22, 2024 | americanbankingnews.comProfound Medical (NASDAQ:PROF) Shares Down 0.1% March 18, 2024 | theguardian.comMorning Mail: MPs’ sporting perks, Putin’s huge win, ‘profound tragedy’ of koala habitat loggingMarch 16, 2024 | msn.com'A dream come true': UMass Chan Medical School students celebrate Match DayMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 14, 2024 | news.yahoo.comNex Benedict died by suicide, says Oklahoma medical examinerMarch 13, 2024 | msn.comHur transcript reveals Biden presidency’s profound and mundane momentsMarch 12, 2024 | morningstar.comProfound Medical Corp PRNMarch 11, 2024 | realmoney.thestreet.comProfound Medical price target lowered by $1.95 at Alliance Global Partners, here's whyMarch 10, 2024 | finance.yahoo.comProfound Medical Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 8, 2024 | insidermonkey.comProfound Medical Corp. (NASDAQ:PROF) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | benzinga.comProfound Medical: Q4 Earnings InsightsMarch 7, 2024 | msn.comProfound Medical GAAP EPS of $0.42 beats by $0.74, revenue of $2M beats by $0.06MMarch 7, 2024 | globenewswire.comProfound Medical Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 6, 2024 | markets.businessinsider.comProfound Medical earnings preview: what to expectMarch 4, 2024 | globenewswire.comProfound Medical to Participate in Barclays 26th Annual Global Healthcare ConferenceFebruary 27, 2024 | globenewswire.comProfound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA ProcedureFebruary 25, 2024 | finanznachrichten.dePESG Research: PESG Industry Updates: Germany's Cannabis Act and Its Impact on the Medical Cannabis LandscapeFebruary 25, 2024 | msn.comExperimental surgery Miranda Jakich endured as a child was reported as a 'medical miracle'. Today she's reclaiming her storyFebruary 24, 2024 | msn.comMothers' dieting habits and self-talk have profound impact on daughters, say psychologistsFebruary 22, 2024 | msn.comAffiliated Medical Services abortion clinic on Milwaukee's east side to reopen in MarchFebruary 22, 2024 | finance.yahoo.comDr. Eric Nepute Cultivates Future Healthcare Leaders with the Inaugural Dr. Eric Nepute Scholarship for Medical StudentsFebruary 22, 2024 | msn.comWhen Living the Black American Experience Causes Sleep Loss and Other Mental Health Struggles — Plus, the Resources That Can HelpSee More Headlines Receive PROF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Profound Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/29/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:PROF CUSIPN/A CIK1628808 Webwww.profoundmedical.com Phone(647) 476-1350Fax64-7847-3739Employees131Year FoundedN/APrice Target and Rating Average Stock Price Target$14.58 High Stock Price Target$20.00 Low Stock Price Target$11.00 Potential Upside/Downside+71.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,570,000.00 Net Margins-396.85% Pretax Margin-398.62% Return on Equity-70.18% Return on Assets-53.80% Debt Debt-to-Equity Ratio0.16 Current Ratio6.58 Quick Ratio5.48 Sales & Book Value Annual Sales$7.20 million Price / Sales28.94 Cash FlowN/A Price / Cash FlowN/A Book Value$1.28 per share Price / Book6.66Miscellaneous Outstanding Shares24,430,000Free Float24,058,000Market Cap$208.39 million OptionableOptionable Beta0.82 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Arun Swarup Menawat MBA (Age 69)Ph.D., Chairman of the Board & CEO Comp: $551.88kMr. Rashed Dewan (Age 56)Chief Financial Officer Comp: $250.37kDr. Mathieu Burtnyk (Age 42)Chief Operating Officer Comp: $246.1kMr. Hartmut Warnken (Age 51)Chief Commercial Officer of Outside US Comp: $224.93kMr. Abbey Goodman (Age 41)Chief Commercial Officer of US Comp: $353.75kMr. Stephen KilmerInvestor RelationsMr. Jacques F. Cornet (Age 68)Senior VP & Product Leader Sonalleve Mr. Matthew Sobczyk C.A.CPA, Assistant Corporate ControllerMr. Levant TinazSoftware DeveloperMore ExecutivesKey CompetitorsAlpha Tau MedicalNASDAQ:DRTSOrchestra BioMedNASDAQ:OBIOAngioDynamicsNASDAQ:ANGOQuipt Home MedicalNASDAQ:QIPTClearPoint NeuroNASDAQ:CLPTView All CompetitorsInstitutional OwnershipGoldman Sachs Group Inc.Bought 2,800 shares on 3/1/2024Ownership: 0.091%Chilton Investment Co. Inc.Bought 10,000 shares on 2/15/2024Ownership: 0.041%Citadel Advisors LLCSold 3,100 shares on 2/15/2024Ownership: 0.000%Royal Bank of CanadaSold 1,674 shares on 2/14/2024Ownership: 1.638%Goldman Sachs Group Inc.Bought 2,800 shares on 2/13/2024Ownership: 0.091%View All Institutional Transactions PROF Stock Analysis - Frequently Asked Questions Should I buy or sell Profound Medical stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Profound Medical in the last twelve months. There are currently 1 hold rating, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PROF shares. View PROF analyst ratings or view top-rated stocks. What is Profound Medical's stock price target for 2024? 3 Wall Street research analysts have issued 12 month price objectives for Profound Medical's stock. Their PROF share price targets range from $11.00 to $20.00. On average, they expect the company's stock price to reach $14.58 in the next twelve months. This suggests a possible upside of 71.0% from the stock's current price. View analysts price targets for PROF or view top-rated stocks among Wall Street analysts. How have PROF shares performed in 2024? Profound Medical's stock was trading at $8.49 at the beginning of the year. Since then, PROF shares have increased by 0.5% and is now trading at $8.53. View the best growth stocks for 2024 here. When is Profound Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our PROF earnings forecast. How were Profound Medical's earnings last quarter? Profound Medical Corp. (NASDAQ:PROF) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.03. The business earned $2.54 million during the quarter, compared to the consensus estimate of $4 million. Profound Medical had a negative trailing twelve-month return on equity of 70.18% and a negative net margin of 396.85%. During the same period in the prior year, the business earned ($0.32) earnings per share. What guidance has Profound Medical issued on next quarter's earnings? Profound Medical updated its fourth quarter 2023 earnings guidance on Wednesday, January, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.9 million-$2.0 million, compared to the consensus revenue estimate of $2.0 million. Who are Profound Medical's major shareholders? Profound Medical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Letko Brosseau & Associates Inc. (4.82%), AIGH Capital Management LLC (2.65%), Raymond James Financial Services Advisors Inc. (2.59%), Timelo Investment Management Inc. (2.50%), Royal Bank of Canada (1.64%) and Worth Venture Partners LLC (0.66%). How do I buy shares of Profound Medical? Shares of PROF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PROF) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Profound Medical Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.